Overview Dividends

(RVMD) Revolution Medicines - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US76155X1000

RAS Inhibitors, Companion Inhibitors, Clinical Pipeline, Targeted Therapy

RVMD EPS (Earnings per Share)

EPS Growth (3Y CAGR): 24.20%
EPS Trend (3Y Correlation): 7.3%

RVMD Revenue

Revenue Growth (3Y CAGR): -80.64%
Revenue Trend (3Y Correlation): -24.2%

Description: RVMD Revolution Medicines November 04, 2025

Revolution Medicines (NASDAQ:RVMD) is a clinical-stage precision-oncology firm that concentrates on “RAS-ON” inhibitors-molecules that bind active RAS variants-to treat cancers driven by mutant RAS signaling. Its pipeline includes three Phase 1 monotherapy candidates (daraxonrasib RMC-6236, elironrasib RMC-6291, and zoldonrasib RMC-9805) and a suite of “RAS companion” agents such as the SOS1 inhibitor RMC-5845 and the selective mTORC1 inhibitor RMC-5552, the latter in Phase 1 and the former in Phase 2. The company’s strategy is to pair these agents with each other or with external therapies to achieve durable tumor suppression.

Key external data points that shape RVMD’s outlook: (1) As of the latest 10-Q, the company reported ~ $210 million in cash and equivalents, giving it runway through late 2026 at current burn rates (~$55 million per quarter). (2) Early Phase 1 data for daraxonrasib showed a 45 % disease-control rate in KRAS-mutant non-small-cell lung cancer, suggesting potential differentiation from competing KRAS-G12C inhibitors. (3) The global market for RAS-targeted therapies is projected to expand at a CAGR of roughly 15 % from 2024-2030, driven by increasing molecular-diagnostic adoption and unmet need in KRAS-mutant tumors.

For a deeper, data-driven assessment of RVMD’s valuation and risk profile, you might explore the analyst tools on ValueRay to see how these fundamentals compare with sector peers.

RVMD Stock Overview

Market Cap in USD	10,999m
Sub-Industry	Biotechnology
IPO / Inception	2020-02-13

RVMD Stock Ratings

Growth Rating	46.6%
Fundamental	29.6%
Dividend Rating	-
Return 12m vs S&P 500	-9.46%
Analyst Rating	4.67 of 5

RVMD Dividends

Currently no dividends paid

RVMD Growth Ratios

Growth Correlation 3m	97.7%
Growth Correlation 12m	-13.5%
Growth Correlation 5y	36.9%
CAGR 5y	40.58%
CAGR/Max DD 3y (Calmar Ratio)	0.83
CAGR/Mean DD 3y (Pain Ratio)	2.15
Sharpe Ratio 12m	-0.23
Alpha	-13.84
Beta	1.264
Volatility	49.14%
Current Volume	2724.4k
Average Volume 20d	2136.2k
Stop Loss	58.5 (-4.1%)
Signal	1.57

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-812.1m TTM) > 0 and > 6% of Revenue (6% = 15.7m TTM)

FCFTA -0.29 (>2.0%) and ΔFCFTA -0.06pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 761.5% (prev 204.8k%; Δ -204.0kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.28 (>3.0%) and CFO -684.9m > Net Income -812.1m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 11.79 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (188.1m) change vs 12m ago 13.93% (target <= -2.0% for YES)

Gross Margin -110.0% (prev -50.5k%; Δ 50.3kpp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 12.35% (prev 0.04%; Δ 12.30pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -998.3 (EBITDA TTM -883.7m / Interest Expense TTM 899.0k) >= 6 (WARN >= 3)

Altman Z'' -4.51

(A) 0.82 = (Total Current Assets 2.18b - Total Current Liabilities 184.5m) / Total Assets 2.43b

(B) -0.91 = Retained Earnings (Balance) -2.20b / Total Assets 2.43b

(D) -3.90 = Book Value of Equity -2.20b / Total Liabilities 564.2m

Total Rating: -4.51 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 29.58

1. Piotroski 0.0pt = -5.0

2. FCF Yield -7.79% = -3.89

3. FCF Margin data missing

4. Debt/Equity 0.07 = 2.50

5. Debt/Ebitda 0.31 = 2.43

6. ROIC - WACC (= -56.78)% = -12.50

7. RoE -41.78% = -2.50

8. Rev. Trend -24.22% = -1.82

9. EPS Trend 7.34% = 0.37

What is the price of RVMD shares?

As of November 09, 2025, the stock is trading at USD 61.01 with a total of 2,724,421 shares traded.
Over the past week, the price has changed by +3.69%, over one month by +31.01%, over three months by +74.56% and over the past year by +3.23%.

Is Revolution Medicines a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Revolution Medicines (NASDAQ:RVMD) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 29.58 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RVMD is around 60.10 USD . This means that RVMD is currently overvalued and has a potential downside of -1.49%.

Is RVMD a buy, sell or hold?

Revolution Medicines has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy RVMD.

Strong Buy: 8
Buy: 4
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the RVMD price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	77.2	26.6%
Analysts Target Price	77.2	26.6%
ValueRay Target Price	68.2	11.9%

RVMD Fundamental Data Overview November 04, 2025

Market Cap USD = 11.00b (11.00b USD * 1.0 USD.USD)
P/S = 9035.0954
P/B = 4.5797
Beta = 1.264
Revenue TTM = 261.6m USD
EBIT TTM = -897.5m USD
EBITDA TTM = -883.7m USD
Long Term Debt = 132.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 13.1m USD (from shortTermDebt, last quarter)
Debt = 132.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -269.7m USD (from netDebt column, last quarter)
Enterprise Value = 8.99b USD (11.00b + Debt 132.8m - CCE 2.14b)
Interest Coverage Ratio = -998.3 (Ebit TTM -897.5m / Interest Expense TTM 899.0k)
FCF Yield = -7.79% (FCF TTM -700.4m / Enterprise Value 8.99b)
FCF Margin = -267.7% (FCF TTM -700.4m / Revenue TTM 261.6m)
Net Margin = -310.4% (Net Income TTM -812.1m / Revenue TTM 261.6m)
Gross Margin = -110.0% ((Revenue TTM 261.6m - Cost of Revenue TTM 549.4m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.70 (Enterprise Value 8.99b / Total Assets 2.43b)
Interest Expense / Debt = 0.68% (Interest Expense 899.0k / Debt 132.8m)
Taxrate = -0.13% (negative due to tax credits) (753.0k / -600.8m)
NOPAT = -898.6m (EBIT -897.5m * (1 - -0.13%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 11.79 (Total Current Assets 2.18b / Total Current Liabilities 184.5m)
Debt / Equity = 0.07 (Debt 132.8m / totalStockholderEquity, last quarter 1.87b)
Debt / EBITDA = 0.31 (negative EBITDA) (Net Debt -269.7m / EBITDA -883.7m)
Debt / FCF = 0.39 (negative FCF - burning cash) (Net Debt -269.7m / FCF TTM -700.4m)
Total Stockholder Equity = 1.94b (last 4 quarters mean from totalStockholderEquity)
RoA = -33.42% (Net Income -812.1m / Total Assets 2.43b)
RoE = -41.78% (Net Income TTM -812.1m / Total Stockholder Equity 1.94b)
RoCE = -43.22% (EBIT -897.5m / Capital Employed (Equity 1.94b + L.T.Debt 132.8m))
RoIC = -46.23% (negative operating profit) (NOPAT -898.6m / Invested Capital 1.94b)
WACC = 10.55% (E(11.00b)/V(11.13b) * Re(10.67%) + D(132.8m)/V(11.13b) * Rd(0.68%) * (1-Tc(-0.00)))
Discount Rate = 10.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 15.44%
Fair Price DCF = unknown (Cash Flow -700.4m)
EPS Correlation: 7.34 | EPS CAGR: 24.20% | SUE: 4.0 | # QB: 1
Revenue Correlation: -24.22 | Revenue CAGR: -80.64% | SUE: -4.0 | # QB: 0

Additional Sources for RVMD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle